KALV – KalVista Pharmaceuticals Inc
Float Short %
44.7
Margin Of Safety %
Put/Call OI Ratio
4.29
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
16.55
Target Price
33.22
Analyst Recom
1
Performance Q
44.71
Relative Volume
0.5
Beta
-0.19
Ticker: KALV
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | KALV | 15.16 | 0.17 | 0.01 | 4866 |
| 2025-12-29 | KALV | 15.16 | 0.17 | 0.01 | 4866 |
| 2025-12-30 | KALV | 15.69 | 0.16 | 0.35 | 5026 |
| 2025-12-31 | KALV | 16.17 | 0.18 | 32.50 | 4924 |
| 2026-01-02 | KALV | 15.47 | 0.21 | 0.75 | 5046 |
| 2026-01-05 | KALV | 15.66 | 0.21 | 5004.00 | 5053 |
| 2026-01-06 | KALV | 15.76 | 1.41 | 0.01 | 10057 |
| 2026-01-07 | KALV | 16.34 | 1.35 | 0.16 | 10249 |
| 2026-01-08 | KALV | 15.84 | 1.34 | 15.69 | 10301 |
| 2026-01-09 | KALV | 16.77 | 1.69 | 3.46 | 12361 |
| 2026-01-12 | KALV | 16.39 | 1.73 | 114.00 | 12807 |
| 2026-01-13 | KALV | 14.94 | 1.75 | 999.99 | 12914 |
| 2026-01-14 | KALV | 15.24 | 2.04 | 0.75 | 14274 |
| 2026-01-15 | KALV | 14.96 | 2.04 | 999.99 | 14282 |
| 2026-01-16 | KALV | 14.58 | 2.04 | 0.09 | 14334 |
| 2026-01-20 | KALV | 15.3 | 4.32 | 1.19 | 9895 |
| 2026-01-21 | KALV | 15.97 | 4.32 | 0.00 | 9972 |
| 2026-01-22 | KALV | 16.55 | 4.29 | 0.11 | 9986 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | KALV | 15.18 | - | - | - |
| 2025-12-29 | KALV | 15.16 | - | - | - |
| 2025-12-30 | KALV | 15.68 | - | - | - |
| 2025-12-31 | KALV | 16.18 | - | - | - |
| 2026-01-02 | KALV | 15.48 | - | - | - |
| 2026-01-05 | KALV | 15.67 | - | - | - |
| 2026-01-06 | KALV | 15.76 | - | - | - |
| 2026-01-07 | KALV | 16.34 | - | - | - |
| 2026-01-08 | KALV | 15.82 | - | - | - |
| 2026-01-09 | KALV | 16.77 | - | - | - |
| 2026-01-12 | KALV | 16.39 | - | - | - |
| 2026-01-13 | KALV | 14.94 | - | - | - |
| 2026-01-14 | KALV | 15.21 | - | - | - |
| 2026-01-15 | KALV | 14.97 | - | - | - |
| 2026-01-16 | KALV | 14.58 | - | - | - |
| 2026-01-20 | KALV | 15.32 | - | - | - |
| 2026-01-21 | KALV | 15.90 | - | - | - |
| 2026-01-22 | KALV | 16.55 | - | - | - |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | KALV | -1.20 | 5.25 | 40.67 |
| 2025-12-29 | KALV | -1.20 | 5.30 | 40.67 |
| 2025-12-30 | KALV | -1.20 | 5.30 | 40.67 |
| 2025-12-31 | KALV | -1.20 | 5.30 | 40.67 |
| 2026-01-02 | KALV | -1.20 | 5.30 | 40.67 |
| 2026-01-05 | KALV | -1.20 | 5.30 | 40.67 |
| 2026-01-06 | KALV | -1.20 | 5.30 | 40.67 |
| 2026-01-07 | KALV | -1.20 | 5.30 | 40.67 |
| 2026-01-08 | KALV | -1.20 | 5.30 | 40.67 |
| 2026-01-09 | KALV | -1.20 | 5.30 | 40.67 |
| 2026-01-12 | KALV | -0.75 | 5.30 | 40.67 |
| 2026-01-13 | KALV | -0.71 | 5.30 | 44.70 |
| 2026-01-14 | KALV | -0.71 | 5.30 | 44.70 |
| 2026-01-15 | KALV | -0.71 | 5.30 | 44.70 |
| 2026-01-16 | KALV | -0.71 | 5.30 | 44.70 |
| 2026-01-20 | KALV | -0.71 | 1.40 | 44.70 |
| 2026-01-21 | KALV | -0.71 | 1.40 | 44.70 |
| 2026-01-22 | KALV | -0.71 | 1.40 | 44.70 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.78
Avg. EPS Est. Next Quarter
-0.6
Insider Transactions
-0.71
Institutional Transactions
1.4
Beta
-0.19
Average Sales Estimate Current Quarter
20
Average Sales Estimate Next Quarter
30
Fair Value
Quality Score
19
Growth Score
25
Sentiment Score
75
Actual DrawDown %
63.2
Max Drawdown 5-Year %
-90.1
Target Price
33.22
P/E
Forward P/E
18.18
PEG
P/S
584.64
P/B
49.18
P/Free Cash Flow
EPS
-4
Average EPS Est. Cur. Y
EPS Next Y. (Est.)
-2.79
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-14242.57
Relative Volume
0.5
Return on Equity vs Sector %
-525.2
Return on Equity vs Industry %
-509.2
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
KalVista Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 270
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today
news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance
stock history KALV – KalVista Pharmaceuticals Inc invest stock market
stock prices KALV premarket after hours
ticker KALV fair value insiders trading